Rinn Song
Clinical Scientist
Dr. Rinn Song joined OVG and the Department of Paediatrics in September 2017 as a Clinician-Scientist and Honorary Consultant in Paediatric Infectious Diseases. Dr. Song completed his medical studies at the Ludwig-Maximilians-University in Munich, Germany, with an MD and a Doctorate Degree in Medicine (MD Res) with a focus on Health Services Research. He completed his clinical training in Paediatrics at New York University in New York, USA, followed by training in Applied Epidemiology and Public Health as an Epidemic Intelligence Service Officer in the TB Division of the US Centers for Disease Control and Prevention. Up until joining the University of Oxford, he has been an affiliated Scientist with the TB Division of the CDC. He completed his training in Paediatric Infectious Diseases at Boston Children’s Hospital/Harvard Medical School and then joined the faculty of the Department of Paediatrics of Harvard Medical School in 2012. He has been a Consultant in Paediatric Infectious Diseases at Boston Children’s Hospital since 2012 and is board certified in Paediatrics and Paediatric Infectious Diseases by the American Board of Pediatrics. He holds an MPH from the Harvard School of Public Health and an MSc in Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine. Dr. Song's primary research interest is paediatric TB, with a specific interest in paediatric TB diagnostics. He has been the PI of a 5 year NIH grant to investigate novel diagnostics as part of a study in Kenya, completed in collaboration with the CDC and KEMRI, and has also been recently working with FIND, Switzerland, on the development and evaluation of novel TB diagnostics.
Recent publications
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.
Journal article
LAMBE T. et al, (2020), Nature Medicine
-
Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: A systematic review.
Journal article
Sudbury EL. et al, (2020), J Infect
-
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
Journal article
Götzinger F. et al, (2020), The Lancet Child & Adolescent Health, 4, 653 - 661